Avail Biomedical Research Institute


The Avail Biomedical Research Institute (ABRI) is the discovery and preclinical research organization of the International network for the Advancement of Viable Applicable Innovations in Life sciences (InAVAIL). InAVAIL consists of R&D-performing organizations, R&D consulting enterprises and service providers working to common aims. This network was established by our scientific leader, Dr. Sabrina Mattoli, to accelerate the development of market-creating innovations by facilitating the sharing of innovative methodologies, data, infrastructures and resources within an international, multidisciplinary and intersectoral consortium.

ABRI is specifically devoted to the advancement of basic and translational research in chronic inflammatory and fibrotic pulmonary diseases of uncertain etiology or complex pathogenesis.

Our research programs are addressed to discover new therapeutic targets for the development of drugs more effective than those currently available, to identify the most appropriate biomarkers of therapeutic responsiveness for treatment personalization, and to test the therapeutic potential of novel stem cell-based approaches.

We have various operative units in Europe, with state-of-the-art laboratories in Munich (Germany) and Warsaw (Poland). The Discovery and Translational Research Center in Munich and the Stem Cell Research Center in Warsaw have GMP/GLP-compliant facilities. These centers also operate as contract research units to provide logistic and highly-qualified scientific and technical support for the conduction of basic research investigations and preclinical studies in the fields of pulmonary medicine and cell-based therapies for pulmonary disorders.


Copyright © 1998-2019, Avail Biomedical Research Institute. All rights reserved.